CO2024001517A2 - Vacunas contra la tuberculosis - Google Patents
Vacunas contra la tuberculosisInfo
- Publication number
- CO2024001517A2 CO2024001517A2 CONC2024/0001517A CO2024001517A CO2024001517A2 CO 2024001517 A2 CO2024001517 A2 CO 2024001517A2 CO 2024001517 A CO2024001517 A CO 2024001517A CO 2024001517 A2 CO2024001517 A2 CO 2024001517A2
- Authority
- CO
- Colombia
- Prior art keywords
- tuberculosis vaccines
- tuberculosis
- vaccines
- disclosure
- antigens
- Prior art date
Links
- 229960002109 tuberculosis vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/32—Mycobacterium
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239278P | 2021-08-31 | 2021-08-31 | |
| US202263392778P | 2022-07-27 | 2022-07-27 | |
| PCT/US2022/075645 WO2023034783A1 (en) | 2021-08-31 | 2022-08-30 | Tuberculosis vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001517A2 true CO2024001517A2 (es) | 2024-03-07 |
Family
ID=83447900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001517A CO2024001517A2 (es) | 2021-08-31 | 2024-02-13 | Vacunas contra la tuberculosis |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240350607A1 (https=) |
| EP (1) | EP4396208A1 (https=) |
| JP (1) | JP2024534178A (https=) |
| KR (1) | KR20240049802A (https=) |
| AU (1) | AU2022339918A1 (https=) |
| CA (1) | CA3226978A1 (https=) |
| CL (1) | CL2024000600A1 (https=) |
| CO (1) | CO2024001517A2 (https=) |
| IL (1) | IL310667A (https=) |
| MX (1) | MX2024001964A (https=) |
| TW (1) | TW202328167A (https=) |
| WO (1) | WO2023034783A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118662620A (zh) * | 2023-03-15 | 2024-09-20 | 康希诺生物股份公司 | 一种肺结核疫苗及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DK2457926T3 (da) | 2005-04-29 | 2015-01-05 | Glaxosmithkline Biolog Sa | Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| DK2964769T3 (en) | 2013-03-05 | 2018-12-10 | Univ Oregon Health & Science | Cytomegalovirus vectors enabling control of T cell targeting |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| CN109843321A (zh) * | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
| US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
-
2022
- 2022-08-30 CA CA3226978A patent/CA3226978A1/en active Pending
- 2022-08-30 KR KR1020247005374A patent/KR20240049802A/ko active Pending
- 2022-08-30 TW TW111132746A patent/TW202328167A/zh unknown
- 2022-08-30 US US18/687,463 patent/US20240350607A1/en active Pending
- 2022-08-30 AU AU2022339918A patent/AU2022339918A1/en active Pending
- 2022-08-30 EP EP22777533.5A patent/EP4396208A1/en active Pending
- 2022-08-30 JP JP2024513275A patent/JP2024534178A/ja active Pending
- 2022-08-30 IL IL310667A patent/IL310667A/en unknown
- 2022-08-30 WO PCT/US2022/075645 patent/WO2023034783A1/en not_active Ceased
- 2022-08-30 MX MX2024001964A patent/MX2024001964A/es unknown
-
2024
- 2024-02-13 CO CONC2024/0001517A patent/CO2024001517A2/es unknown
- 2024-02-27 CL CL2024000600A patent/CL2024000600A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022339918A1 (en) | 2024-02-08 |
| CA3226978A1 (en) | 2023-03-09 |
| TW202328167A (zh) | 2023-07-16 |
| MX2024001964A (es) | 2024-03-01 |
| EP4396208A1 (en) | 2024-07-10 |
| CL2024000600A1 (es) | 2024-09-06 |
| JP2024534178A (ja) | 2024-09-18 |
| US20240350607A1 (en) | 2024-10-24 |
| WO2023034783A1 (en) | 2023-03-09 |
| IL310667A (en) | 2024-04-01 |
| KR20240049802A (ko) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021005774A2 (es) | Lípidos con amina ionizables | |
| MX2021000193A (es) | Selección de epítopos de vacunas personalizadas contra el cáncer. | |
| MX2020006688A (es) | Celulas presentadoras de antigenos artificiales y metodos de uso. | |
| ECSP22072586A (es) | VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG | |
| MX2020009857A (es) | Conjugados de interleucina-2 (il-2). | |
| CO2023016246A2 (es) | Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados y sus usos | |
| PY2126530A (es) | VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2 | |
| CL2021002141A1 (es) | Anticuerpos claudina 6 y usos de los mismos. | |
| MX2020005584A (es) | Vacunacion con particulas de replicon y adyuvante oleoso. | |
| CL2024000600A1 (es) | Vacunas contra la tuberculosis | |
| CU20210077A7 (es) | Extractos bacterianos estables como fármacos | |
| CL2015002513A1 (es) | Vacuna acelular contra pertussis | |
| MX2015002699A (es) | Expresion de proteinas ksac quimerica y metodo para producir proteinas solubles mediante alta presion. | |
| CO2021010786A2 (es) | Toxinas apxia, apxiia y apxiiia inactivadas | |
| CL2024000580A1 (es) | Vectores de hcmv recombinante y usos de estos | |
| CO2021012294A2 (es) | Composiciones de lawsonia intracellularis y métodos de uso de las mismas | |
| AR089995A1 (es) | Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas | |
| CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
| BR112022020298A2 (pt) | Vacinas, adjuvantes e métodos para gerar uma resposta imune | |
| CL2019003801A1 (es) | Nuevas formulaciones orales de belinostato. | |
| MX2021005303A (es) | Composiciones inmunogenicas. | |
| CO2022013715A2 (es) | Vacuna inactivada contra el virus sars-cov-2 | |
| CO2025003056A2 (es) | Proteína g antirrábica y sus usos | |
| MX2020001954A (es) | Composiciones para el cuidado bucal y sus usos. | |
| MX2021009790A (es) | Adyuvantes y formulaciones para vacunas. |